X
53.41
-1.32 (-2.41%)
| 前收盘价格 | 54.73 |
| 收盘价格 | 54.43 |
| 成交量 | 1,263,915 |
| 平均成交量 (3个月) | 1,470,539 |
| 市值 | 5,162,907,136 |
| 价格/销量 (P/S) | 591.55 |
| 股市价格/股市净资产 (P/B) | 3.95 |
| 52周波幅 |
| 营业利益率 (TTM) | -969.84% |
| 稀释每股收益 (EPS TTM) | -3.22 |
| 总债务/股东权益 (D/E MRQ) | 1.23% |
| 流动比率 (MRQ) | 17.66 |
| 营业现金流 (OCF TTM) | -196.85 M |
| 杠杆自由现金流 (LFCF TTM) | -128.49 M |
| 资产报酬率 (ROA TTM) | -22.03% |
| 股东权益报酬率 (ROE TTM) | -31.60% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Xenon Pharmaceuticals Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.14% |
| 机构持股比例 | 103.51% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 97.00 (Baird, 81.61%) | 购买 |
| 中 | 77.00 (44.17%) | |
| 低 | 64.00 (Wedbush, 19.83%) | 购买 |
| 平均值 | 78.83 (47.59%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 61.33 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Deutsche Bank | 10 Mar 2026 | 90.00 (68.51%) | 购买 | 60.61 |
| HC Wainwright & Co. | 10 Mar 2026 | 74.00 (38.55%) | 购买 | 60.61 |
| Wedbush | 10 Mar 2026 | 64.00 (19.83%) | 购买 | 60.61 |
| Wells Fargo | 10 Mar 2026 | 68.00 (27.32%) | 购买 | 60.61 |
| Baird | 09 Mar 2026 | 97.00 (81.61%) | 购买 | 62.76 |
| Needham | 09 Mar 2026 | 80.00 (49.78%) | 购买 | 62.76 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合